Back to results
US 6,436,938 B1Granted
Combination treatment for depression
AssigneePfizer Inc.
InventorHarry Ralph Howard, Jr.
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of treating depression, especially refractory depression, in a mammal, including a human, by administering to the mammal a sigma receptor ligand in combination with an antidepressant agent. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a sigma receptor ligand and a serotonin reuptake inhibitor.
Claims30
A pharmaceutical composition for the treatment of depression, in a mammal, comprising:
- (a) a compound that exhibits activity, respectively, as an SRI antidepressant, or a pharmaceutically acceptable salt thereof;
- (b) a sigma receptor ligand or pharmaceutically acceptable salt thereof;
- and (c) a pharmaceutically acceptable carrier;
- wherein the active agents “a” and “b” above are present in amounts that render the composition effective in treating, respectively, anxiety or refractory depression.
1 more element
A method of treating depression, in a mammal, comprising administering to said mammal:
- (a) a compound that exhibits activity as an SRI antidepressant, or a pharmaceutically acceptable salt thereof;
- and (b) a sigma receptor ligand or pharmaceutically acceptable salt thereof, wherein the active agents “a” and “b” above are present in amounts that render the combination of the two agents effective in treating, respectively, anxiety or refractory depression.
Dependencies are inferred from the claim text.